Adage Capital Partners
KROS icon

Adage Capital Partners’s Keros Therapeutics KROS Stock Holding History

Adage Capital Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-230,000
Closed -$10.5M – 907
2024
Q2 		$10.5M Buy
230,000
+40,000
+21% +$2.15M 0.02% 598
2024
Q1 		$12.6M Buy
+190,000
New +$11.3M 0.02% 559

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners's KROS Position: Q3 2024 in Review

Adage Capital Partners sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 230,000 shares — an estimated $10.5M sold.

Adage Capital Partners first reported a position in KROS in Q1 2024 and held it in 2 quarters. The position peaked at $12.6M in Q1 2024. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

  • Adage Capital Partners reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Adage Capital Partners sold 230,000 Keros Therapeutics shares in Q3 2024, an estimated $10.5M.
  • Adage Capital Partners first reported a position in Keros Therapeutics in Q1 2024 and held it in 2 quarters.
  • Adage Capital Partners's Keros Therapeutics position peaked at $12.6M in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on Adage Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.